The latest biotech news

geneuro multiple sclerosis neuron viral dna

News and Trends 12 Mar 2019

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis

An antibody that blocks the action of a hidden viral protein encoded by our genome shows encouraging signs of slowing down the progression of multiple sclerosis, according to the Swiss biotech GeNeuro which carried out the research. GeNeuro’s monoclonal antibody drug targets the hidden viral protein because it’s linked to the occurrence of multiple sclerosis, […]

March 12, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 11 Mar 2019

Danish Biotech to Develop CRISPR-Based Microbiome Treatments

SNIPR Biome has raised €43M in Series A funds to develop treatments that precisely target ‘bad’ bacteria using CRISPR gene editing, while keeping the rest of the patient’s microbiome intact. Founded with €2.6M seed investment from the Lundbeck Foundation in 2017, SNIPR Biome was the first exploratory investment for the Danish organisation’s Emerge fund, which […]

March 11, 2019 - 2 minutesmins - By Helen Albert

News and Trends 11 Mar 2019

Monthly Injection Proves as Good as Daily Pills Against HIV in Phase III

Two phase III trials conducted by ViiV Healthcare have concluded that a monthly injection of two anti-HIV drugs is as effective as the standard daily treatment taken by people infected with HIV. The results showed that, after 11 months, the monthly treatment achieved virus suppression levels of over 90% and similar to those of conventional […]

March 11, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Mar 2019

HIV Drug Shows Promise for Treating Ulcerative Colitis Patients

A small molecule drug, developed by the company Abivax for treating HIV, has also shown promise for patients with the inflammatory bowel disease ulcerative colitis, reducing the disease severity consistently for over six months. Abivax tested the drug on patients with moderate-to-severe cases of ulcerative colitis, an inflammatory bowel condition that causes rectal bleeding and […]

March 8, 2019 - 3 minutesmins - By Jonathan Smith

influenza virus antiviral drugs atriva therapeutics germany tuebingen 1

News and Trends 8 Mar 2019

Flu Resistant to Antivirals? This Biotech Has a Drug for That

We are visiting the medieval German city of Tübingen this week. It hosts the biotech Atriva Therapeutics, which is developing antiviral drugs for influenza that can circumvent drug resistance. Mission: To make antiviral drugs that, unlike conventional drugs, target the host cell instead of the virus. This can prevent the virus from building resistance to […]

March 8, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 6 Mar 2019

Second Patient Achieves HIV Remission After Bone Marrow Transplant to Treat Cancer

For the second time in history, an HIV-positive patient with blood cancer has achieved HIV remission following a customized bone marrow transplant to treat their cancer from an HIV-resistant donor. The HIV-positive patient received a bone marrow transplant to treat the blood cancer Hodgkin’s lymphoma, from which he also suffered. The researchers used this cancer […]

March 6, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 5 Mar 2019

Seventure Continues Microbiome Investment Success with Second Fund

After the success of the world’s first fund dedicated to companies in nutrition, digital health, and the microbiome, the French venture capital firm Seventure Partners has completed the first closing of a second microbiome fund, which is expected to total €200M. The fund is the successor to Seventure’s Health for Life Capital fund, which was […]

March 5, 2019 - 3 minutesmins - By Jonathan Smith

biogen nightstar therapeutics gene therapy ophthalmology

News and Trends 4 Mar 2019

Biogen Acquires UK Biotech Developing Gene Therapy for Blindness

The big US biotech Biogen has agreed to acquire Nightstar Therapeutics for €773M ($877M), including Nightstar’s candidate gene therapies for inherited blindness. Expected to be complete by mid-2019, Biogen’s acquisition of Nightstar bags it the UK company’s most advanced program. Currently in phase III, the therapy targets choroidemia, an incurable genetic condition which causes progressive […]

March 4, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 1 Mar 2019

Rapid Response mRNA Vaccine Facility Gets €30M Funding

An mRNA vaccine facility, run by the German biotech CureVac, has received a €30M development grant to rapidly manufacture vaccines for regions hit by outbreaks of rabies, yellow fever and emerging diseases. CureVac is a company that develops vaccines made of mRNA, a molecule that lets cells translate genes into proteins. The company’s drug candidates […]

March 1, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 1 Mar 2019

Update: Hansa Biopharma Applies for EMA Market Approval for Kidney Transplant Drug

Update (01/03/2019): Hansa Biopharma (previously named Hansa Medical) has filed an application for marketing authorization for imlifidase with the EMA also for use in patients undergoing kidney transplants. Update (18/10/2018): Imlifidase has just been given Fast Track Designation by the FDA for application in transplantation. The designation should accelerate the treatment through the FDA’s regulatory process, with […]

March 1, 2019 - 3 minutesmins - By Jonathan Smith

hookipa cancer vaccine hiv cytomegalovirus

News and Trends 28 Feb 2019

Austrian Biotech Raises €33.2M to Fund Cancer Vaccines

A Series D round of €33.2M ($37.4M) is to help the biotech Hookipa advance the clinical development of therapeutic vaccines for virus-based cancers, as well as a prophylactic vaccine for cytomegalovirus, which can infect patients undergoing organ transplants. Currently at the preclinical stage, Hookipa’s therapeutic vaccines are designed to tackle cancers that are caused […]

February 28, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 27 Feb 2019

UK Biotech Gets Huge Grant to Launch Off-the-Shelf CAR-T Cancer Therapy to Clinic

The UK biotech Cell Medica has received a €7.6M ($8.7M) grant from the Cancer Prevention and Research Institute of Texas to advance an off-the-shelf CAR-T cell therapy that can work not only in blood cancer but also in solid tumors. The funding will help the company to develop a special type of CAR-T cell therapy […]

February 27, 2019 - 3 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis

Danish Biotech to Develop CRISPR-Based Microbiome Treatments

Monthly Injection Proves as Good as Daily Pills Against HIV in Phase III

HIV Drug Shows Promise for Treating Ulcerative Colitis Patients

Flu Resistant to Antivirals? This Biotech Has a Drug for That

Second Patient Achieves HIV Remission After Bone Marrow Transplant to Treat Cancer

Seventure Continues Microbiome Investment Success with Second Fund

Biogen Acquires UK Biotech Developing Gene Therapy for Blindness

Rapid Response mRNA Vaccine Facility Gets €30M Funding

Update: Hansa Biopharma Applies for EMA Market Approval for Kidney Transplant Drug

Austrian Biotech Raises €33.2M to Fund Cancer Vaccines

UK Biotech Gets Huge Grant to Launch Off-the-Shelf CAR-T Cancer Therapy to Clinic

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!